Re-appointment of Ms. Esha Padmanabhan Achan (DIN:10350369), as a Non-Executive Independent Director of the Company.
ROSSARI · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Rossari Biotech's Board approved the re-appointment of Ms. Esha Padmanabhan Achan as a Non-Executive Independent Director for a second term of 3 years (October 21, 2026 to October 20, 2029), subject to shareholder approval. Ms. Achan is a finance professional with 33 years of experience, having served as Group President at Glenmark Pharmaceuticals and Bajaj. The Board also granted 830,050 stock options under the ESOP 2019 plan at an exercise price of Rs. 537 per option, vesting over 4 years in a 20%/20%/20%/40% schedule.
The re-appointment of an experienced independent director signals continued governance stability. The large ESOP grant (covering 830,050 shares) may help retain and motivate employees but could have minor dilution impact for existing shareholders.